Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00177190 · ClinicalTrials.gov registry record
In Vitro Evaluation of Immune Responses in Cutaneous T-Cell Lymphoma (CTCL)
A clinical trial, sponsored by University of Pittsburgh.
- Completed
- Registry status
- 8
- Enrollment target
NCT00177190: Completed study, sponsored by University of Pittsburgh.
NCT00177190 is a clinical trial that has completed, run by University of Pittsburgh. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00177190 has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- 8 participants
- Enrollment target
Study Summary
This is an in vitro evaluation of cutaneous T-cell lymphoma using patients' blood and tissue to evaluate immune responses related to identified tumor populations and dendritic/CD 8 cells.
Primary Outcome
Evaluate the feasibility of the preparation of dendritic cells (DCs), CD8 and Sezary cells (all CD4 positive) in vitro, obtained from the buffy coats or a skin biopsy from an area with tumor involvement of subjects with cutaneous t-cell lymphoma (CTCL) and Sezary syndrome (leukemic stage of CTCL)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2002-06 |
| Est. Completion | 2006-01 |
What the finished NCT00177190 record still lists
NCT00177190 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 8 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00177190 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00177190 about?
NCT00177190 is a clinical study titled "In Vitro Evaluation of Immune Responses in Cutaneous T-Cell Lymphoma (CTCL)". This is an in vitro evaluation of cutaneous T-cell lymphoma using patients' blood and tissue to evaluate immune responses related to identified tumor populations and dendritic/CD 8 cells.
What is the current status of trial NCT00177190?
This trial is currently completed. The enrollment target is 8 participants. The study started on 2002-06. Estimated completion is 2006-01.
Who is sponsoring clinical trial NCT00177190?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia